<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581658</url>
  </required_header>
  <id_info>
    <org_study_id>1245.53</org_study_id>
    <nct_id>NCT01581658</nct_id>
  </id_info>
  <brief_title>Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase I, Open-label, Parallel-group Study to Investigate Pharmacokinetics, Pharmacodynamics and Safety of a Single 25 mg Dose of Empagliflozin in Japanese Type 2 Diabetes Patients With Different Degrees of Renal Impairment in Comparison to Type 2 Diabetes Patients With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effect of the different degrees of renal
      impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral
      administration of high dose BI10773 as a single dose in Japanese patients with type 2
      diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2012</start_date>
  <completion_date type="Actual">November 1, 2012</completion_date>
  <primary_completion_date type="Actual">November 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Urinary Glucose Excretion (UGE)</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>change from baseline in total urinary glucose excretion (UGE) to 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve of the Analyte in Plasma</measure>
    <time_frame>Predose and 20 minutes (min), 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 36h 48h, 72h and 96h after drug administration</time_frame>
    <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration</measure>
    <time_frame>Predose and 20 minutes (min), 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 36h 48h, 72h and 96h after drug administration</time_frame>
    <description>Maximum concentration of the analyte in plasma</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI10773 medium dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI10773 medium dose tablet single dose group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI10773 medium dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI10773 medium dose tablet single dose group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI10773 Medium dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI10773 medium dose tablet single dose group 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI10773 Medium dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI10773 medium dose tablet single dose group 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>BI10773 medium dose tablet single dose</description>
    <arm_group_label>BI10773 medium dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>BI10773 medium dose tablet single dose</description>
    <arm_group_label>BI10773 Medium dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>BI10773 medium dose tablet single dose</description>
    <arm_group_label>BI10773 medium dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>BI10773 medium dose tablet single dose</description>
    <arm_group_label>BI10773 Medium dose group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetes patients

          -  Glycosylated haemoglobin&gt;= 6.1% (Japan Diabetes Society)

          -  Estimated glomerular filtration rate based on the modification of diet in renal
             disease-formula at screening , of &gt;= 15 mL/min/1.73m2

        Exclusion criteria:

          -  Any evidence of significant disease (other than renal impairment)

          -  Moderate and severe concurrent liver function impairment

          -  Gastrointestinal tract surgery, that might affect absorption and elimination of drugs

          -  Diseases of the central nervous system (such as epilepsy), psychiatric disorders, or
             neurological disorders

          -  Chronic or relevant acute infections

          -  Participation in another trial with investigational drug administration within 30 days
             prior to study drug administration or during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.53.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Renal Function</title>
          <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
        </group>
        <group group_id="P2">
          <title>Mild Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
        </group>
        <group group_id="P4">
          <title>Severe Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Renal Function</title>
          <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
        </group>
        <group group_id="B2">
          <title>Mild Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
        </group>
        <group group_id="B4">
          <title>Severe Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="3.1"/>
                    <measurement group_id="B2" value="67.5" spread="4.4"/>
                    <measurement group_id="B3" value="65.9" spread="5.5"/>
                    <measurement group_id="B4" value="62.0" spread="7.9"/>
                    <measurement group_id="B5" value="65.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Urinary Glucose Excretion (UGE)</title>
        <description>change from baseline in total urinary glucose excretion (UGE) to 24 hours</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Treated patients who had complete urine sample (baseline and 24 hours) for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Urinary Glucose Excretion (UGE)</title>
          <description>change from baseline in total urinary glucose excretion (UGE) to 24 hours</description>
          <population>Treated patients who had complete urine sample (baseline and 24 hours) for analyses.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74969.3" spread="4840.68" lower_limit="64978.6" upper_limit="84960.0"/>
                    <measurement group_id="O2" value="62577.4" spread="5751.25" lower_limit="50707.5" upper_limit="74447.4"/>
                    <measurement group_id="O3" value="57889.0" spread="4861.26" lower_limit="47855.9" upper_limit="67922.2"/>
                    <measurement group_id="O4" value="23725.1" spread="5235.06" lower_limit="12920.5" upper_limit="34529.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve of the Analyte in Plasma</title>
        <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity</description>
        <time_frame>Predose and 20 minutes (min), 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 36h 48h, 72h and 96h after drug administration</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve of the Analyte in Plasma</title>
          <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity</description>
          <population>Treated patients</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7480" spread="16.2"/>
                    <measurement group_id="O2" value="9630" spread="15.9"/>
                    <measurement group_id="O3" value="10800" spread="9.55"/>
                    <measurement group_id="O4" value="11400" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>128.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>105.962</ci_lower_limit>
            <ci_upper_limit>156.604</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>143.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>118.306</ci_lower_limit>
            <ci_upper_limit>174.848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>152.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>125.287</ci_lower_limit>
            <ci_upper_limit>185.166</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration</title>
        <description>Maximum concentration of the analyte in plasma</description>
        <time_frame>Predose and 20 minutes (min), 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 36h 48h, 72h and 96h after drug administration</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration</title>
          <description>Maximum concentration of the analyte in plasma</description>
          <population>Treated patients</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" spread="19.1"/>
                    <measurement group_id="O2" value="984" spread="30.8"/>
                    <measurement group_id="O3" value="971" spread="26.2"/>
                    <measurement group_id="O4" value="990" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>93.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.236</ci_lower_limit>
            <ci_upper_limit>121.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>92.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.216</ci_lower_limit>
            <ci_upper_limit>119.305</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.630</ci_lower_limit>
            <ci_upper_limit>121.674</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From trial drug intake until the end-of-study examination visit, up to 12 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Renal Function</title>
          <description>25 mg empagliflozin taken as a single dose for patients with normal renal function</description>
        </group>
        <group group_id="E2">
          <title>Mild Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with mild renal impairment</description>
        </group>
        <group group_id="E3">
          <title>Moderate Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with moderate renal impairment</description>
        </group>
        <group group_id="E4">
          <title>Severe Renal Impairment</title>
          <description>25 mg empagliflozin taken as a single dose for patients with severe renal impairment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

